Published in Hum Gene Ther on April 10, 1998
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol (1999) 2.94
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res (2008) 2.67
Whole cell vaccines--past progress and future strategies. Semin Oncol (2012) 0.93
Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas. Vaccine (2007) 0.81
Gene therapy in pancreatic cancer. World J Gastroenterol (2014) 0.81
Peptidases released by necrotic cells control CD8+ T cell cross-priming. J Clin Invest (2013) 0.79
A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Ann Surg Oncol (2014) 0.78
Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines. Immunology (2001) 0.77
Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). Surg Today (2010) 0.76
Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a post-Barrett's esophagus setting. Dig Dis Sci (2008) 0.76
CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation. Br J Cancer (2003) 0.75
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 6.97
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol (2000) 4.23
Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science (1989) 4.19
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 3.98
A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. Nature (1987) 3.96
A fixed site of DNA replication in eucaryotic cells. Cell (1980) 3.78
Molecular and cellular events of T cell development. Adv Immunol (1989) 3.50
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res (2001) 3.32
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
Supercoiled loops and eucaryotic DNA replicaton. Cell (1980) 3.24
Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res (2000) 2.91
Deletion of self-reactive thymocytes occurs at a CD4+8+ precursor stage. Nature (1988) 2.84
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 2.81
CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med (1998) 2.69
Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci U S A (1987) 2.57
Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity (1999) 2.55
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res (2001) 2.50
Characterization of T cell receptor gamma chain expression in a subset of murine thymocytes. Science (1986) 2.40
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A (1995) 2.27
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A (1996) 2.24
Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity (2000) 2.13
Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol (1998) 2.10
Effects of cyclosporine A on T cell development and clonal deletion. Science (1988) 2.08
T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol Rev (1987) 2.07
Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am (1998) 2.03
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med (1994) 2.01
Differential expression of two distinct T-cell receptors during thymocyte development. Nature (1987) 1.95
Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A (1998) 1.95
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol (2013) 1.92
The fate of CD4-8- T cell receptor-alpha beta+ thymocytes. J Immunol (1991) 1.90
Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst (1995) 1.90
In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity (1996) 1.89
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res (2000) 1.86
Localization of SV40 genes within supercoiled loop domains. Nucleic Acids Res (1980) 1.68
Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther (1999) 1.63
Carrier detection in X-linked agammaglobulinemia by analysis of X-chromosome inactivation. N Engl J Med (1987) 1.63
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res (1997) 1.58
Tumour antigens. A new look for the 1990s. Nature (1994) 1.56
Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J Immunol (1999) 1.51
CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med (2000) 1.48
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res (2001) 1.47
Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res (1995) 1.45
A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med (1995) 1.44
Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther (2000) 1.41
Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer (1998) 1.38
In vivo CD4+ T cell tolerance induction versus priming is independent of the rate and number of cell divisions. J Immunol (2000) 1.36
Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A (1999) 1.30
Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer (2005) 1.29
The relationship of the nuclear matrix to cellular structure and function. Adv Enzyme Regul (1978) 1.23
Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol (1994) 1.17
Sequence analysis of nuclear matrix associated DNA from rat liver. Exp Cell Res (1980) 1.17
Early genetic events in T cell development analyzed by in situ hybridization. J Exp Med (1987) 1.16
Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med (1996) 1.13
Chemotherapy: friend or foe to cancer vaccines? Curr Opin Mol Ther (2001) 1.10
Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine (2000) 1.08
A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther (1998) 1.07
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer (2012) 1.07
Participation in screening colonoscopy in first-degree relatives from patients with colorectal cancer. Ann Oncol (2007) 1.05
Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3. J Immunol (1988) 1.04
Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther (2001) 1.04
The unfolding story of T cell receptor gamma. FASEB J (1987) 1.04
Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res (1993) 1.03
Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis. Scand J Immunol (1997) 1.03
Activation properties of T cell receptor-gamma delta hybridomas expressing diversity in both gamma- and delta-chains. J Immunol (1988) 1.03
Cancer vaccines. J Clin Oncol (1999) 0.99
Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther (1995) 0.98
Molecular mechanisms for lineage commitment in T cell development. Semin Immunol (1990) 0.98
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys (2000) 0.98
Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol (1996) 0.97
Hematopoietic cell transplantation in the twitcher mouse. The effects of pretransplant conditioning with graded doses of busulfan. Transplantation (1993) 0.94
Cyclosporin A inhibits positive selection and delays negative selection in alpha beta TCR transgenic mice. J Immunol (1994) 0.94
Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol (1998) 0.94
Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice. Blood (1991) 0.93
[Diagnosis of and therapy for hepatocellular carcinoma]. Z Gastroenterol (2013) 0.91
Murine tumor antigens: is it worth the search? Curr Opin Immunol (1996) 0.91
Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res (2001) 0.91
Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. Z Gastroenterol (2010) 0.90
Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol (2001) 0.89
T cell receptor gamma/delta chain diversity. J Exp Med (1988) 0.89
Aplastic crisis due to extensive bone marrow necrosis in sickle cell disease. Arch Intern Med (1982) 0.89
Immunoglobulin gene rearrangements in remission bone marrow specimens from patients with acute lymphoblastic leukemia. Blood (1986) 0.89
Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer? Curr Opin Investig Drugs (2001) 0.89
Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem (1995) 0.88
Inhibition of experimental vasospasm with anti-intercellular adhesion molecule-1 monoclonal antibody in rats. Stroke (1997) 0.88
Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. AIDS (1995) 0.87
Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility. Cytotherapy (2005) 0.87
MHC-based diagnostics and therapeutics - clinical applications for disease-linked genes. Immunol Today (1999) 0.87
Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer (2000) 0.85
Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J Immunother Emphasis Tumor Immunol (1996) 0.84
Immune based therapies in cancer. Histol Histopathol (2007) 0.84